Displaying drugs 4651 - 4675 of 5128 in total
EI-001
Investigational
Nedometinib
Investigational
C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide
Experimental
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
Danicamtiv
Danicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).
Investigational
4-S-Glutathionyl-5-pentyl-tetrahydro-furan-2-ol
Experimental
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Leupeptin
Investigational
Metelimumab
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
Josamycin
A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
Investigational
Altiratinib
Investigational
C-(1-hydrogyl-beta-D-glucopyranosyl) formamide
Experimental
Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate
Experimental
3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC
Experimental
N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE
Experimental
(2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE
Experimental
R-348
Investigational
Sevasemten
Sevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).
Investigational
HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE
Experimental
Benzoyl-tyrosine-alanine-fluoro-methyl ketone
Experimental
Displaying drugs 4651 - 4675 of 5128 in total